- Markets
- Healthcare
- VINEETLAB
VINEETLAB
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Vineet Laboratories Approved Resignation Of Satish Pandurang Samant As CEO
May 29 (Reuters) - Vineet Laboratories Ltd VINL.NS:
APPROVED RESIGNATION OF SATISH PANDURANG SAMANT FROM OFFICE OF CEO
Source text for Eikon: ID:nBSE5H7NXM
Further company coverage: VINL.NS
(([email protected];;))
May 29 (Reuters) - Vineet Laboratories Ltd VINL.NS:
APPROVED RESIGNATION OF SATISH PANDURANG SAMANT FROM OFFICE OF CEO
Source text for Eikon: ID:nBSE5H7NXM
Further company coverage: VINL.NS
(([email protected];;))
Vineet Laboratories Appoints Satish Pandurang Samant As CEO
Oct 16 (Reuters) - Vineet Laboratories Ltd VINL.NS:
APPOINTS SATISH PANDURANG SAMANT AS CEO
Source text for Eikon: ID:nBSE9zrhBl
Further company coverage: VINL.NS
(([email protected];))
Oct 16 (Reuters) - Vineet Laboratories Ltd VINL.NS:
APPOINTS SATISH PANDURANG SAMANT AS CEO
Source text for Eikon: ID:nBSE9zrhBl
Further company coverage: VINL.NS
(([email protected];))
India's Vineet Laboratories March-Quarter Profit Rises
May 29 (Reuters) - Vineet Laboratories Ltd VINL.NS:
MARCH-QUARTER PROFIT 35.5 MILLION RUPEES VERSUS 32.8 MILLION RUPEES
MARCH-QUARTER TOTAL INCOME FROM OPERATIONS 572 MILLION RUPEES VERSUS 555.9 MILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: VINL.NS
(([email protected];))
May 29 (Reuters) - Vineet Laboratories Ltd VINL.NS:
MARCH-QUARTER PROFIT 35.5 MILLION RUPEES VERSUS 32.8 MILLION RUPEES
MARCH-QUARTER TOTAL INCOME FROM OPERATIONS 572 MILLION RUPEES VERSUS 555.9 MILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: VINL.NS
(([email protected];))
Events:
Dividend
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Vineet Laboratories do?
Vineet Laboratories Limited, formerly known as Ortin Laboratories Limited, is an Indian company established in 2016. It specializes in Drug Intermediates & Bulk Drugs, offering API Intermediates, Fine Chemicals, Reagents, and Research & Development.
Who are the competitors of Vineet Laboratories?
Vineet Laboratories major competitors are Omkar Pharmachem, Veerhealth Care, Concord Drugs, Guj. Inject (Kerala), Kabra Drugs, Zenith Health Care, Unick Fix-A-Form. Market Cap of Vineet Laboratories is ₹31 Crs. While the median market cap of its peers are ₹30 Crs.
Is Vineet Laboratories financially stable compared to its competitors?
Vineet Laboratories seems to be less financially stable compared to its competitors. Altman Z score of Vineet Laboratories is 2.08 and is ranked 5 out of its 8 competitors.
Does Vineet Laboratories pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Vineet Laboratories latest dividend payout ratio is 13.89% and 3yr average dividend payout ratio is 13.89%
How has Vineet Laboratories allocated its funds?
Companies resources are allocated to majorly unproductive assets like Inventory, Short Term Loans & Advances
How strong is Vineet Laboratories balance sheet?
Balance sheet of Vineet Laboratories is moderately strong, But short term working capital might become an issue for this company.
Is the profitablity of Vineet Laboratories improving?
No, profit is decreasing. The profit of Vineet Laboratories is -₹7.74 Crs for TTM, ₹1.03 Crs for Mar 2024 and ₹1.25 Crs for Mar 2023.
Is the debt of Vineet Laboratories increasing or decreasing?
The debt of Vineet Laboratories is decreasing. Latest debt of Vineet Laboratories is ₹38.96 Crs as of Dec-24. This is less than Mar-24 when it was ₹43.52 Crs.
Is Vineet Laboratories stock expensive?
Vineet Laboratories is not expensive. Latest PE of Vineet Laboratories is 0.0, while 3 year average PE is 48.03. Also latest EV/EBITDA of Vineet Laboratories is 0.0 while 3yr average is 12.63.
Has the share price of Vineet Laboratories grown faster than its competition?
Vineet Laboratories has given lower returns compared to its competitors. Vineet Laboratories has grown at ~-17.04% over the last 2yrs while peers have grown at a median rate of 20.27%
Is the promoter bullish about Vineet Laboratories?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Vineet Laboratories is 35.85% and last quarter promoter holding is 35.85%.
Are mutual funds buying/selling Vineet Laboratories?
There is Insufficient data to gauge this.